In contrast, a German study on 372 pediatric AML patients showed that KRAS mutations were significantly associated with unsatisfactory therapeutic responses and increased early mortality rates; on the other hand, NRAS mutations were associated with better therapeutic responses [98]. Here, KRAS is linked to acute myeloid leukemia.